Watch ADIL. Know when insiders buy.
One email the day a filing lands. Free.
ADIL
ADIAL PHARMACEUTICALS, INC.
7.12
+0.46 +6.91%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
52
WATCH · shorts 52
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $18.7MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$57.8MNET CASH —52W 1.36 – 10.50SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$52M | −$52M | — | -11.25 | −$6.4M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$2M | −$2M | — | -1.48 | −$1.6M | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$1.9M | −$2M | — | -11.48 | −$1.3M | — | — | Mar 5 |
| Q3 2025 · Sep 30 | — | — | — | −$1.8M | −$1.8M | — | -0.08 | −$1.8M | — | — | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$1.9M | −$2M | — | -4.61 | −$1.7M | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$2.3M | −$2.2M | — | -8.52 | −$1.6M | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$1.9M | −$2.1M | — | -65.44 | −$1.5M | — | — | Mar 5 |
| Q3 2024 · Sep 30 | — | — | — | −$2.2M | −$2.2M | — | -0.38 | −$1.7M | — | — | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$2.3M | −$2.5M | — | -0.59 | −$2.1M | — | — | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$1.8M | −$6.5M | — | -2.19 | −$1.6M | — | — | Nov 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$1.8M | −$1.9M | — | -0.74 | −$1.2M | — | — | Mar 4 |
| Q3 2023 · Sep 30 | — | — | — | −$1.4M | −$1.4M | — | -1.18 | −$1.4M | — | — | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$7.8M | −$8M | — | -11.93 | −$6.5M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$8.3M | −$13.2M | — | -68.01 | −$6.9M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$6.9M | −$5.1M | — | -3.60 | −$6.8M | — | — | $2K | — |
| FY2022 · to Dec 31 | — | — | −$10.9M | −$12.7M | — | -12.71 | −$11.2M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$19.3M | −$19.4M | — | -1.04 | −$11.9M | $65K | −$12M | — | — |
| FY2020 · to Dec 31 | — | — | −$10.9M | −$10.9M | — | -0.87 | −$7.6M | — | — | — | — |
Every number comes from ADIAL PHARMACEUTICALS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.